DemeRx’s noribogaine for alcohol use disorder is now the first US ibogaine derivative in clinical development

The headline is real. The FDA accepted DemeRx’s Investigational New Drug application for DMX-1001 — oral noribogaine — to develop a treatment for alcohol use disorder. This is the first time the FDA has cleared an ibogaine-derived molecule for clinical study in the United States. For a field that has carried ibogaine as an underground reality for thirty years, that’s a meaningful institutional shift.

What the Phase 1 multiple-ascending-dose data actually showed: DMX-1001 was safe and well-tolerated across 20–80 mg daily. The cardiac safety story — which is the story most likely to make or break this molecule’s path forward — was that QT-interval effects were observed and were dose-related, but the company and the FDA reviewers concluded they were not clinically relevant at the doses tested. Ibogaine itself has a known cardiac risk profile that has driven dozens of fatalities in unregulated treatment settings. Noribogaine is ibogaine’s primary active metabolite, with — DemeRx argues — therapeutic effect minus the most acute cardiac and psychoactive properties.

That argument is the one the cardiology and addiction-medicine communities will pressure-test through Phase 2, which the company expects to start in 2027 after a planned alcohol-interaction study.

The clinical-need framing matters here. Existing FDA-approved medications for AUD — naltrexone, acamprosate, disulfiram — work, but their numbers needed to treat are ≥7. The recently published semaglutide + CBT trial reported an NNT of 4.3, which the field is still digesting. If noribogaine produces durable reductions in heavy drinking days at safe doses, it would be added to a pipeline that’s getting more crowded — and more interesting — than at any point in the past three decades.

What this is not: a license for unsupervised use of ibogaine, noribogaine, or any iboga-derived product. The substances available outside research settings carry the cardiac risks the FDA has been worried about, and the people most likely to be harmed are the people who can’t afford to wait three years for Phase 2.

Why this matters for people in recovery

If you’re in active recovery from alcohol use, the practical implication today is small. Phase 2 is two years out and Phase 3 longer than that. But if you’ve felt that the existing AUD medications didn’t fit you, the pipeline is starting to widen. That’s worth knowing.

If you’re considering ibogaine or noribogaine outside a clinical trial, please talk to your physician about cardiac risk first. The molecules are not interchangeable, and the supervision matters.

For navigation through current alcohol use disorder treatment, Rize Recovery can help match you to providers in your insurance network.